你可能會喜歡
We are looking for a JUNIOR PATHOLOGIST (at least 1 year of residency training) to join our group and lead one of our translational efforts in kidney cancer. Please contact us if you are interested and willing to spend at least 2 years in the lab.
Many congratulations Berkay Simsek for being a recipient of the KCRS 2025 Merit Awards for Translational Research @simsek_berkay_ @kidneycan @MassGenBrigham #KCRS25 #kidneycancer
#KCRS25 Oral Abstract: @simsek_berkay_ @BrighamWomens links CD163+ macrophages in RCC tumors to better outcomes with nivolumab. A potential new target for immunotherapy. Read all the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25 #AcceleratingCures
Pathologist representation at this year’s #KCRS25, one of my most important and favorite meetings each year. 🔬🩺🩻 #gupathology #workingtogethertofightRCC @PayalKapur5 @Unclassified1 @drmehrarohit @kidneycan @OncoAlert @urotoday
So proud to be part of this incredible research team! #KCRS25 #pathology #kidneycancer @kidneycan
We are looking for a JUNIOR PATHOLOGIST (at least 1 year of residency training) to join our group and lead one of our translational efforts in kidney cancer. Please contact us if you are interested and willing to spend at least 2 years in the lab.
Thanks to our friends at Cure Today for letting me share some advice for new patients. 👊👊 @DanaFarber @DrChoueiri @DanaFarber_GU @kidneycan @TheJimmyFund @DanaFarberNews curetoday.com/view/finding-s…
Celebrating Dr Sabina Signoretti @BrighamWomens work and dedication over the years to @DanaFarber @BrighamWomens @df_hcc Pathology! cc: @LabSignoretti @kaelin_lab @harvardmed
Phase 1/2 Design of the HIF2a inhibitor NKT2152-101 showed response rate of 20% with an ‘in class’ toxicity profile #ESMO24 . The long half like makes it distinct and there in now a dose to take to randomised trials. Advantages over belzurifan are unclear. 2 doses being pursued.
Sarcomatoid RCC #kidneycancer : Diagnostic Updates and Therapeutic Implications. Comprehensive talk by @SabinaSign16728 @BrighamWomens 👉epigenomics, genetics and inflammed phenotype of Sarcomatoid RCC & Rx implications #KCRS24 @kidneycan @DrChoueiri @TalalZarif1 @OncoAlert
Kicking off the Trials in Progress session with #ARCITECT evaluating Botensilimab+Balstilimab for pts with mRCC A trial that aims to "raise the tail" and a fantastic presentation by @MikeSerzanMD #KCRS24 @kidneycan @OncoAlert
Great work from these presenters!
Wonderful Pathology session on KCRS - State of the Science. “This is an Exciting and a Fantastic time to be a Pathologist!” @kidneycan
The #INTerpath-004 trial explores the combination of pembro + personalized mRNA #vaccine for the adjuvant treatment of pts with RCC. Inspiring talk by @DrChoueiri at #KCRS24! @kidneycan @DanaFarber_GU @OncLive
🟢 Outstanding presentation at #KCRS24 @drmehrarohit 🟠 Role of Pathologist in Kidney Cancer Diagnostics and Research 🟠 Highlighting the morphologic diversity in renal tumors and its diagnostic implications. 🟠 Emphasis on understanding mechanisms to improve patient care.…
We are super interested in the IVC thrombus @UTSWUrology @utswcancer @UTSWHemeOnc! @PayalKapur5 shows IVC correlates and Angioscore for as a biomarker for angiogenic driven tumor. @KCPUTSW #KCRS24 @kidneycan
Prognostic and Predictive Biomarkers in #kidneycancer Very insightful talk by @PayalKapur5 @UTSWMedCenter 👉Tumor thrombus grading predicts metastasis free survival better than primary RCc grading & more👇#KCRS24 @kidneycan @DrChoueiri @JBrugarolas @HHammersMD
Thank you Chuck for sharing! It’s very inspiring! Advocacy, research, and patient care unite to accelerate the cure! We can’t do it alone – we need each other! @kidneycan @DrChoueiri @advocatekidneys #KCRS24 @OncoAlert @CJSTRAV3 #Advocate @HHammersMD @neerajaiims @yekeduz_emre…
Brilliant insights from @tompowles1 @QMBCI. Excellent use of Twitter polls to reconcile tough clinical scenarios (eg IO rechallenge following adj pembro). Shocking to hear rates of IO receipt in real world series - great point from Tom - use the best tx first. @DrChoueiri…
#KCRS24 Session 8: Rapid Abstract Presentations are underway! Tertiary Lymphoid Structures in Sarcomatoid RCC @NickSalgia Brain-Specific Tropism in mRCC @rmelias2 Latino Ethnicity & Gut Microbiome in mRCC @ReginaBarCar #KidneyCancer #AcceleratingCures
Wrapping #kcrs24! Started my day with rock the run 5k and finished it with insightful discussions and inspiring moments. So glad to be part of kidney cancer research but also part of a great team along the way of curing this cancer!
United States 趨勢
- 1. Columbus 65.6K posts
- 2. #SwiftDay 8,256 posts
- 3. #WWERaw 20.1K posts
- 4. #IDontWantToOverreactBUT N/A
- 5. #TSTheErasTour 2,074 posts
- 6. $ZOOZ 1,021 posts
- 7. #IndigenousPeoplesDay 2,481 posts
- 8. Knesset 113K posts
- 9. Marc 36K posts
- 10. Good Monday 39.1K posts
- 11. Victory Monday 1,383 posts
- 12. Thanksgiving 43.3K posts
- 13. Flip 49.5K posts
- 14. Broadcom 1,531 posts
- 15. Branch 47.8K posts
- 16. Penta 4,729 posts
- 17. Rod Wave 3,025 posts
- 18. Kairi 9,938 posts
- 19. The Final Show 26.2K posts
- 20. Happy 250th 1,863 posts
你可能會喜歡
-
ari hakimi
@arihakimi -
James Brugarolas
@JBrugarolas -
Dana-Farber Lank Center for Genitourinary Oncology
@DanaFarber_GU -
David Braun
@BraunMDPhD -
Chris Labaki
@Chrislabaki1 -
Katy Beckermann
@katy_beckermann -
Wenxin (Vincent) Xu
@VincentWenxinXu -
Tanya Dorff
@TDorffOnc -
Srinivas Viswanathan
@srviswanathan -
Atish Choudhury, MD PhD
@AtishChoudhury -
Michael Serzan, MD
@MikeSerzanMD -
Gretchen Vaughan
@GEVaughan1 -
Stephanie Berg
@bergsa83 -
KidneyCancerProgram
@KCPUTSW -
Charlene Mantia
@CharleneMantia
Something went wrong.
Something went wrong.